Reviewer’s report

Title: Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series

Version: 0 Date: 22 Nov 2018

Reviewer: Ji Hwan Lee

Reviewer’s report:

The authors presented RAM cases treated with intravitreal ranibizumab or conbercept. Although cases were well managed with favorable outcomes, there have been already several reports on the use of anti-VEGF in RAM patients. This study seems to add an evidence of using intravitreal conbercept.

1. In OCT images of all patients (fig.1-4), B-scan lines should be added to know of which locations are shown.

2. The conclusion 'Intravitreal ranibizumab or conbercept could provide anatomical and visual satisfactory results for retinal arterial macroaneurysm' cannot be drawn from these cases, because there are possibilities of spontaneous resolution. It may be better to conclude that intravitreal ranibizumab or conbercept may be used as a therapeutic option for symptomatic RAM Pts.

3. There are some grammatic errors. An additional English proof would be necessary.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript
**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal